Literature DB >> 12242604

Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis.

M Isabel Lucena1, Raúl J Andrade, Gianni Tognoni, Ramón Hidalgo, Felipe Sanchez De La Cuesta.   

Abstract

OBJECTIVE: To describe the prescribing patterns for liver disease management.
METHODS: A multicenter cross-sectional prospective observational study was carried out in 25 Spanish hospitals. Inpatients, admitted to gastrointestinal and liver units with a diagnosis of liver cirrhosis, were included in five centrally assigned index days between February and June 1999. Information was collected about demographic variables and pharmacological treatments used on admission and recommended at discharge.
RESULTS: Five hundred and sixty-eight patients (70% men, mean age 61 years) were studied. Alcoholic cirrhosis of the liver accounted for 44% of the sample, ascites being the most prevalent complication. The most frequent diuretic schedule on admission was the combination of spironolactone and furosemide at a ratio of 1 (100 mg/40 mg). Hospitalization resulted in an increase in the percentage of patients that received the combination at a ratio higher than 1. Diuretics were a major cause of adverse drug events on admission (7.5%). Ulcer-healing drugs showed a notable increase at discharge (35%; range 10-59%) compared with 24% (6-37%) on admission. Utilization rates at discharge were 65% (59-74%) for diuretics, 51% (38-76%) for laxatives, 31% (0-75%) for vitamin K, 24% (4-53%) for beta-adrenergic blocking agents, and 13% (0-47%) for nitrates, which were significantly higher than on admission.
CONCLUSION: These results provide the first quantitative data of drug utilization in liver disease and highlight the wide variability in prescribing practices across centers and the higher than expected use of non-evidence-based treatments, especially vitamin K and antiulcer drugs.

Entities:  

Mesh:

Year:  2002        PMID: 12242604     DOI: 10.1007/s00228-002-0474-1

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  Drug use for non-hepatic associated conditions in patients with liver cirrhosis.

Authors:  M Isabel Lucena; Raúl J Andrade; Gianni Tognoni; Ramón Hidalgo; Felipe Sanchez de la Cuesta
Journal:  Eur J Clin Pharmacol       Date:  2003-04-09       Impact factor: 2.953

2.  Proton pump inhibitor prescription abuse and sepsis in cirrhosis.

Authors:  Antonio Picardi; Umberto Vespasiani-Gentilucci
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

3.  Use of paracentesis in hospitalized patients with decompensated cirrhosis and ascites: opportunities for quality improvement.

Authors:  John Brooling; Rony Ghaoui; Peter K Lindenauer; Jennifer Friderici; Tara Lagu
Journal:  J Hosp Med       Date:  2014-10-28       Impact factor: 2.960

Review 4.  Treatment of alcoholic liver disease.

Authors:  Ina Bergheim; Craig J McClain; Gavin E Arteel
Journal:  Dig Dis       Date:  2005       Impact factor: 2.404

Review 5.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

6.  A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification.

Authors:  Julie Steelandt; Elodie Jean-Bart; Sylvain Goutelle; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

7.  Medicine use and medicine-related problems in patients with liver cirrhosis: a systematic review of quantitative and qualitative studies.

Authors:  Ejaz Cheema; Aliaa Al-Aryan; Abdullah Al-Hamid
Journal:  Eur J Clin Pharmacol       Date:  2019-05-11       Impact factor: 2.953

8.  Outcomes associated with a mandatory gastroenterology consultation to improve the quality of care of patients hospitalized with decompensated cirrhosis.

Authors:  Rony Ghaoui; Jennifer Friderici; David J Desilets; Tara Lagu; Paul Visintainer; Angelica Belo; Jorge Sotelo; Peter K Lindenauer
Journal:  J Hosp Med       Date:  2014-12-30       Impact factor: 2.960

9.  Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis.

Authors:  Carmen C Franz; Sabin Egger; Christa Born; Alexandra E Rätz Bravo; Stephan Krähenbühl
Journal:  Eur J Clin Pharmacol       Date:  2011-08-13       Impact factor: 2.953

10.  Use of the Model for End-Stage Liver Disease (MELD) score to predict 1-year survival of Japanese patients with cirrhosis and to determine who will benefit from living donor liver transplantation.

Authors:  Masatoshi Ishigami; Takashi Honda; Akihiko Okumura; Tetsuya Ishikawa; Makoto Kobayashi; Yoshiaki Katano; Yasuhiro Fujimoto; Tetsuya Kiuchi; Hidemi Goto
Journal:  J Gastroenterol       Date:  2008-07-01       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.